News
The University Hospital of Marseille spotlighted our collaborative work towards a new therapeutic approach for relapse and refractory AML patients using the lead drug candidate of Advanced BioDesign.
Advanced BioDesign's winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments. As part of the France 2030 plan, the "i-Demo" scheme supports the development of highly innovative, high added-value products and services to strengthen France's scientific and technological capabilities.
Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.